scholarly journals Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis

2021 ◽  
Author(s):  
Jane C Figueiredo ◽  
Eric J Jacobs ◽  
Christina C Newton ◽  
Mark A Guinter ◽  
William G Cance ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Statistical Tests ◽  
Distant Metastases ◽  
Specific Mortality ◽  
Regular Aspirin ◽  
Secondary Analyses ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Background Aspirin-use reduces colorectal cancer (CRC) incidence, but there is limited evidence regarding associations of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) with CRC-specific survival. Methods This prospective analysis includes women and men from the Cancer Prevention Study-II Nutrition Cohort who were cancer-free at baseline (1992 or 1993) and diagnosed with CRC during incidence follow-up through 2015. Detailed information on aspirin and non-aspirin NSAID-use was self-reported on questionnaires at baseline, in 1997, and every 2 years thereafter. Pre- and post-diagnosis data were available for 2,686 and 1,931 participants without distant-metastases, respectively, among whom 512 and 251 died from CRC during mortality follow-up through 2016. Secondary analyses examined associations between pre-diagnosis aspirin-use and stage at diagnosis (distant-metastatic versus localized or regional). All statistical tests were two-sided. Results Long-term regular use of aspirin (>15 times per month) before diagnosis was associated with lower CRC-specific mortality (multivariable-adjusted hazard ratio (HR)= 0.69; 95% CI = 0.52–0.92). Post-diagnosis regular aspirin use was not statistically significantly associated with risk of CRC-specific mortality overall (HR = 0.82; 95% CI = 0.62–1.09), although participants who began regular aspirin use only after their diagnosis were at lower risk than participants who did not use aspirin at both the pre-and post-diagnosis periods (HR = 0.60; 95% CI = 0.36–0.98). Long-term aspirin use before diagnosis was also associated with lower odds of diagnosis with distant metastases (multivariable-adjusted odds ratio = 0.73; 95% CI = 0.53–0.99). Conclusions Our results suggest that long-term aspirin use before a diagnosis of non-metastatic colorectal cancer may be associated with lower CRC-specific mortality after diagnosis, consistent with possible inhibition of micro-metastases before diagnosis.

Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care

2011 ◽  
Vol 127 (1) ◽  
pp. 284-285 ◽  
Author(s):  
Timo Buhl ◽  
Heike C. Meynberg ◽  
Kjell M. Kaune ◽  
Peter Hünecke ◽  
Michael P. Schön ◽  
...  
Keyword(s):  
Long Term Follow Up ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Colorectal cancer nutritional and quality-of-life parameters predict patients outcomes after radiotherapy: Long-term follow-up from a prospective randomized controlled trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14570-14570
Author(s):  
P. Ravasco ◽  
I. Monteiro Grillo ◽  
M. Camilo
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Controlled Trial ◽  
Distant Metastases ◽  
Disease Outcome ◽  
Nutritional Counseling ◽  
Diet Intake

14570 Background: Long term data of our published randomized trial of nutritional therapy in colorectal cancer showed that nutritional counseling optimizes pts prognosis. This study aimed to search whether outcomes were affected by individual nutritional & Quality of Life (QoL) parameters after nutrition intervention and radiotherapy (RT). Methods: Data were obtained from the trial pts’ records: G1 (n=37) on individualized nutritional counseling & education (regular foods), G2 (n=37) ad lib+polymeric protein supplements & G3 (n=37) ad lib intake. After RT, current intake (diet history), nutritional status (PG-SGA) & QoL scores (EORTC) were evaluated; their ability to predict survival, disease outcome [loco regional recurrence (LRR), distant metastases] & late RT toxicity (permanent flatulence, abdominal distension, diarrhea) were analyzed after a median follow-up of 3.7 (2.0–5.8) yrs. Results: Energy/protein intakes had decreased in G3 (p<0.01) & increased in G1>G2, p=0.007; wasting only occurred in G3>G2 (p<0.05); QoL scores worsened in G3>G2 (p<0.05) yet improved in G1, p<0.01. On multivariate analyzis of coded time-dependent variables: poorer diet intake, nutritional wasting & worse QoL scores were associated with decreased survival (p<0.002), LRR (p=0.01), distant metastases (p=0.005) & late RT toxicity, p<0.003. Landmark analysis showed that pts with nutritional intake/status & QoL deterioration, had significantly lower survival (hazard ratio [HR]: 8.25; 95% CI 2.74–26.47; p<0.001), worse disease outcome (HR: 8.15; 95% CI 2.22–25.40; p<0.002) & more severe late RT toxicity (HR: 7.15; 95% CI 2.25–16.11; p<0.004). Conclusions: In colorectal cancer after RT, poor diet intake, wasting & deteriorated QoL look as if significant predictors of survival, treatment response & late RT toxicity; such patients are prone to a more aggressive clinical course. No significant financial relationships to disclose.

scholarly journals Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function

2021 ◽  
pp. 152-157
Author(s):  
A. P. Rebrov ◽  
A. V. Aparkina ◽  
E. V. Kchondkaryan
Keyword(s):  
Liver Function ◽  
Liver Enzymes ◽  
Genetically Engineered ◽  
Term Therapy ◽  
Acute Liver Damage ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Long Term Therapy

The purpose of the study is to analyze the state of liver function in patients with spondyloarthritis taking non-steroidal anti-inflammatory drugs continuously for 24 months. Materials and methods of the study include 198 patients with spondyloarthritis. The prospective study involved 36 patients with spondyloarthritis who took non-steroidal anti-inflammatory drugs (NSAIDs) prescribed by a physician in the community for 24 months. The level of liver enzymes in blood serum at admission and in dynamics was studied. The increase of liver enzymes was detected in 12 (6.06%) of 198 patients with spondyloarthritis. Among them 6 (50%) patients took methotrexate, 1 (8.33%) - genetically engineered drug, 2 (16.67%) patients-sulfasalazine and 3 (25%) - nonsteroidal anti - inflammatory drugs. 19.4% of patients were registered with a periodic increase of transaminase levels on the background of NSAIDs for the last 24 months. At the same time, no cases of acute liver damage or progressive deterioration of liver function requiring discontinuation of therapy were recorded during the entire follow-up period.

scholarly journals Comparison of Efficacy and Safety of Duloxetine and Nonsteroidal Anti-inflammatory Drugs in Subacromial Impingement Syndrome

2021 ◽  
Author(s):  
Li Zhao ◽  
Li Teng ◽  
Feng Xu ◽  
Huayun Zhang ◽  
Zhigang Xie ◽  
...  
Keyword(s):  
Pain Intensity ◽  
Stage I ◽  
Subacromial Impingement Syndrome ◽  
Treatment Groups ◽  
End Of Treatment ◽  
Loxoprofen Sodium ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Background: Subacromialimpingement syndrome (SIS) is characterized by shoulder pain and restriction in range of motion (ROM), which lead to debility and decrease quality of life (QoL). Duloxetine could provide persistent long-term pain relief in chronic musculoskeletal pain. Therefore, we aimed to investigate the efficacy of duloxetine in stage I or II SIS patients through comparing the nonsteroidal anti-inflammatory drugs (NSAIDs) treatment.Methods: The patients diagnosed with stage I or II SISwere randomly assigned into the duloxetine group (N= 37) and NSAIDs group (N= 37). Duloxetine group patients started on oral duloxetine 40 mg per day for one week and then titrated up to 60 mg per day for one week. NSAIDs group patients received oral loxoprofen sodium tablets 60mg3 times a day for two weeks. The standard measures for investigating the efficacy include pain intensity (VAS), ROM, shoulder functional status, and the QoL at baseline, end of treatment, and at 1 and 3 months follow-up.Results: 74 eligible patients completed the treatment and evaluation. Both treatment groups improved significantly from baseline over time. And all parameters of pain intensity, shoulder functionalstatus and QoL in the duloxetine group were significantly better than those in the NSAIDs group.And no one manifested SIS recurrence and side effects during the entire follow-up period.Conclusions: Both duloxetine and NSAIDs can be beneficial in the rehabilitation of stage I or II SIS patients. Moreover, duloxetine resulted in improvements in outcomes greater than NSAIDs for the treatment of SIS. The current results indicated that duloxetine treatment might be used as a new safe and effective alternative for SIS. Given the encouraging results of this study, it would be worthwhile to confirm our findings in randomized placebo-controlled multicentre clinical trials.

scholarly journals THU0423 ADHERENCE TO URATE-LOWERING THERAPY IN PATIENTS WITH SEVERE GOUT WHO RECEIVED СANAKINUMAB FOLLOWING A 5-YEAR RETROSPECTIVE ANALYSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 449.1-450
Author(s):  
M. Elisеev ◽  
O. Sheliabina
Keyword(s):  
Interleukin 1 ◽  
Symptomatic Treatment ◽  
Symptomatic Therapy ◽  
Lowering Therapy ◽  
Long Term Follow Up ◽  
Inflammatory Drugs ◽  
Acute Attacks ◽  
Anti Inflammatory

Background:The adherence to lowering therapy for gout is low, including in chronic severe gout. Whether interleukin 1 inhibitors may contribute to better adherence is unknown.Objectives:To compare adherence to urate-lowering therapy in patients with severe gout who received canakinumab versus patients who received standard anti-inflammatory therapy (NSAIDs, glucorticoids, colchicine).Methods:Of the 513 patients with gout observed at the V.A. Nasonova Research Institute of Rheumatology, Moscow from 2013 to 2014 y 247 patients with the most severe gout, requiring regular symptomatic treatment, were selected. Of these, 25 patients (3 (12%) women and 22 (88%) men), the average age of 54.5 ± 12.7 g, received (at least 1) canakinumab injection of 150 mg subcutaneously as a symptomatic therapy, the remaining 222 patients (men) mean age 51.9 ± 11.4 g. received standard anti-inflammatory therapy (colchicine (55% of patients), glucorticoids (5%), NSAIDs (40%), or a combination of these (3%). On average, after 4,8 ± 1.7 years, a comparative analysis of adherence to reducing therapy was carried out, as well as the need for anti-inflammatory therapy and assessment of adherence according to the Score compliance on the scale of the Moriscy-Green patients who received and did not receive canakinumab.Results:Evaluation was available in 180 patients (16 who received canakinumab and 164 who received standard anti-inflammatory therapy) who were initially given reducible therapy. 11 patients died (2 patients (8%) who received canakinumab and 9 (4%) patients on standard anti-inflammatory therapy), 56 patients (7 (28%) and 49 (22%), respectively) were not available for observation. Adherence to urate-lowering therapy was better in patients who received canakinumab (see table 1).Table 1.Score compliance on the scale of the Moriscy-GreenAdherence to therapyPatients receiving canakinumab, (n %)Patients receiving standard anti-inflammatory therapy, (n %)р=High (> 4 points)14 (87)83 (51)0,07Moderate (3 points)2 (13)46 (28)0,13Low (2 and <points)035 (21)0,03The likelihood of maintaining the target uric acid level when taking urate-lowering drugs in patients who previously received canakinumab was higher (12 patients (75%) who received canakinumab and 32 (20%) patients received standard anti-inflammatory therapy (p = 0.005).During the year preceding the analysis, there were no acute attacks of arthritis in 12 (75%) patients who received canakinumab and 46 (28%) patients received standard anti-inflammatory therapy (p = 0.002).132 patients who previously received regular anti-inflammatory therapy and received standard anti-inflammatory therapy and 1 patient (1 attack) (p = 0.005) who previously received canakinumab took anti-inflammatory drugs over the past year due to the development of exacerbations (an average of 3 seizures per year): NSAIDs (54%) or colchicine (46%).Conclusion:Therapy with interleukin 1 Kanakinumab may contribute to a better adherence to lowering therapy and isidentified with a lesser need for symptomatic therapy with long-term follow-up.Disclosure of Interests: :Maxim Elisеev Speakers bureau: Novartis, Menarini Group, Alium, Olga Sheliabina: None declared

Sign in / Sign up

Export Citation Format

Share Document